Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088530 · ClinicalTrials.gov registry record · Phase 3
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
A Phase 3 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT00088530: Completed Phase 3 study, sponsored by CTI BioPharma.
NCT00088530 is a Phase 3 study that has completed, run by CTI BioPharma. The registered enrollment target is 140 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088530, a Phase 3 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).
Interventions
- DRUG pixantrone, cyclophosphamide, vincristine, rituximab, prednisone
- DRUG Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088530
The ClinicalTrials.gov registry entry for NCT00088530 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pixantrone, cyclophosphamide, vincristine, rituximab, prednisone is the first listed.
NCT00088530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088530 about?
NCT00088530 is a clinical study titled "BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)". BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quin...
What is the current status of trial NCT00088530?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2004-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00088530?
The interventions under investigation include: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone (DRUG), Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab (DRUG).
Who is sponsoring clinical trial NCT00088530?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.